Obinutuzumab (called afutuzumab until 2009[1]) is a humanized monoclonal antibody, originated by Glycart Biotechnology AG and developed by Biogen Idec, Chugai Pharmaceutical Co., and Hoffmann-La Roche Inc. for the treatment of lymphoma.[2] It acts as an immunomodulator.[3][4]
Obinutuzumab targets CD20 and kills B cells.[2]
Obinutuzumab was approved under the tradename Gazyva by the US FDA in 2013, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients. Patients treated with Gazyva had median survival of 23 months before death or disease progression, compared with 11.1 months for patients on chemotherapy alone.[5]
UK availability[edit]
In October 2014, NICE announced that NHS England would not fund use of the drug, due to data uncertainties in Roche's application.[6]
References[edit]
Jump up ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
^ Jump up to: a b Robak, T (2009). "GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies". Current opinion in investigational drugs (London, England : 2000) 10 (6): 588–96. PMID 19513948.
Jump up ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Afutuzumab, American Medical Association.
Jump up ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
Jump up ^ Associated Press, published in the New York Times. November 1, 2013 F.D.A. Clears New Cancer-Fighting Drug From Roche
Jump up ^ "NICE denies Roche cancer drug due to ‘data uncertainties’". PM Live. Retrieved 3 October 2014.
Obinutuzumab targets CD20 and kills B cells.[2]
Obinutuzumab was approved under the tradename Gazyva by the US FDA in 2013, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients. Patients treated with Gazyva had median survival of 23 months before death or disease progression, compared with 11.1 months for patients on chemotherapy alone.[5]
UK availability[edit]
In October 2014, NICE announced that NHS England would not fund use of the drug, due to data uncertainties in Roche's application.[6]
References[edit]
Jump up ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
^ Jump up to: a b Robak, T (2009). "GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies". Current opinion in investigational drugs (London, England : 2000) 10 (6): 588–96. PMID 19513948.
Jump up ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Afutuzumab, American Medical Association.
Jump up ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
Jump up ^ Associated Press, published in the New York Times. November 1, 2013 F.D.A. Clears New Cancer-Fighting Drug From Roche
Jump up ^ "NICE denies Roche cancer drug due to ‘data uncertainties’". PM Live. Retrieved 3 October 2014.
No comments:
Post a Comment